6533b7ddfe1ef96bd127540a

RESEARCH PRODUCT

A 35-year effective treatment of catecholaminergic polymorphic ventricular tachycardia with propafenone

Torsten KonradCarsten NalenzThomas RostockBoris A. HoffmannBjörn LangeAlexandra Marx

subject

medicine.medical_specialtyPolymorphic premature ventricular beatsmedicine.drug_classCase ReportPropafenone030204 cardiovascular system & hematologyCatecholaminergic polymorphic ventricular tachycardiaRyanodine receptor 203 medical and health sciences0302 clinical medicinePropafenoneInternal medicineMedicineEffective treatment030212 general & internal medicineExercise-induced syncopeBeta blockerbusiness.industrymedicine.diseaseBlockadeExercise-induced syncopeCatecholaminergic polymorphic ventricular tachycardiacardiovascular systemCardiologyAntiarrhythmic effectCardiology and Cardiovascular MedicinebusinessRyanodine receptor mutationmedicine.drug

description

Key Teaching Points • Despite proven catecholaminergic polymorphic ventricular tachycardia (CPVT) with pathogen RyR2 mutation and recurrent syncope, patients could have a favorable long-term outcome over 35 years under treatment. • Propafenone could be effective for treatment of patients with CPVT. • The beneficial effect of the monotherapy with propafenone in our patient may result from the combined antiarrhythmic effect of this drug with Na+ channel blockade and beta blocker capabilities.

yearjournalcountryeditionlanguage
2018-04-01HeartRhythm Case Reports
https://doi.org/10.1016/j.hrcr.2018.04.003